Advance your Real World Evidence (RWE) clinical studies with our expert CRO support, from real-world data strategy to regulatory-ready evidence generation. Ensure compliance, data integrity, and actionable insights with our end-to-end RWE solutions.
ProRelix Research delivers end-to-end Real World Evidence (RWE) CRO support, enabling robust clinical insights through strategically integrated study design, real-world data analytics, and regulatory-aligned execution. By effectively applying real-world evidence in clinical trials, sponsors strengthen evidence generation, accelerate development timelines, and support confident, data-driven regulatory and market access decisions.
Real-World Evidence (RWE) in clinical trials uses real-world data (RWD) from sources like electronic health records, patient registries, and insurance claims to evaluate drug safety, effectiveness, and outcomes. By leveraging RWE, pharmaceutical companies and healthcare organizations can complement traditional clinical trials, make data-driven decisions, and support regulatory submissions with evidence that reflects real patient experiences and routine clinical practice. RWE also enables faster insights into treatment patterns, helps identify unmet medical needs, and supports personalized medicine strategies. Its integration strengthens the overall evidence generation process and informs better healthcare decisions.
RWE in pharma refers to evidence derived from real-world data to understand how drugs and therapies perform in everyday clinical settings. It helps pharma companies assess treatment effectiveness, patient safety, and market value beyond controlled clinical trials. By analyzing RWE, pharmaceutical organizations can optimize clinical development, improve post-marketing surveillance, and guide regulatory strategy. It also supports value-based healthcare initiatives and demonstrates the real-world impact of therapies on patient populations.
Real-World Evidence (RWE) studies help assess how drugs, medical devices, and therapies perform in routine clinical practice. They provide valuable insights into safety, effectiveness, and patient outcomes, complementing traditional clinical trials and supporting regulatory, payer, and clinical decision-making.
Track patient outcomes in real-world clinical settings without intervention. These studies help identify treatment patterns, long-term safety signals, and effectiveness across diverse populations, providing actionable evidence for clinicians and regulators.
Designed to evaluate therapies in routine healthcare environments, pragmatic trials measure real-world effectiveness while maintaining the rigor of clinical trial methodology. They help bridge the gap between controlled trials and everyday practice.
Structured databases that collect longitudinal data on patients with specific diseases or conditions. Registries provide insights into disease progression, treatment responses, and quality-of-life outcomes, supporting both clinical research and healthcare.
Utilize insurance claims, electronic health records (EHRs), and other secondary data sources to analyze treatment utilization, adherence, healthcare costs, and outcomes. These analyses are critical for understanding population-level trends and informing decision-making.
Monitor therapies after regulatory approval to detect adverse events, long-term safety issues, and real-world effectiveness. These studies support pharmacovigilance, label updates, and ongoing risk-benefit assessments.
Feature | Real-World Evidence (RWE) | Clinical Trials (CT) |
Purpose | Evaluates how treatments perform in routine healthcare settings and real patient populations | Determines safety and efficacy of interventions under controlled, predefined conditions |
Study Design | Observational, non-interventional, or pragmatic studies using real-world data | Interventional, randomized, and protocol-driven experimental studies |
Data Sources | Electronic health records, claims databases, registries, patient-reported outcomes | Trial-specific data collected through site visits, monitoring, and case report forms |
Patient Population | Broad and diverse populations reflecting real clinical practice | Highly selected participants based on strict inclusion and exclusion criteria |
Regulatory Value | Supports post-marketing surveillance, label expansion, and real-world effectiveness assessments | Forms the primary evidence base for regulatory approvals and initial market authorization |
Real-World Evidence (RWE) study design enables the generation of actionable insights from real-world data. By integrating diverse data sources and employing rigorous planning, RWE studies provide evidence to support informed clinical strategies and regulatory decisions.
Real-world evidence (RWE) studies are increasingly used in clinical research to generate actionable insights on drug safety, effectiveness, and patient outcomes. By analyzing data from electronic health records (EHR), insurance claims, patient registries, and patient-reported outcomes, these studies capture real-life treatment performance across diverse patient populations. Leading real-world evidence companies like ProRelix Research provide expertise in designing and executing RWE studies, ensuring robust data, regulatory alignment, and meaningful insights for healthcare decision-making.
Collecting data from multiple real-world sources ensures comprehensive insights across varied patient populations.
By reflecting actual clinical practice, RWE studies provide evidence of treatment effectiveness in real-life scenarios.
Recognized by agencies like the FDA and EMA, these studies assist in regulatory decision-making, post-marketing surveillance, and label expansions.
Sponsors can leverage real-world insights to guide clinical strategies and optimize patient outcomes.
RWE studies often complement traditional trials, reducing study timelines and costs while maintaining scientific validity.
ProRelix Research is a leading CRO offering end-to-end Real World Evidence services, ensuring regulatory alignment, robust study design, high-quality data analytics, & reliable evidence generation to support regulatory submissions & healthcare decision-making.
We develop scientifically structured real-world data strategies aligned with study objectives, therapeutic areas, and regulatory expectations. Each study design emphasizes methodological clarity, reduced bias, and meaningful evidence generation using diverse real-world data across healthcare environments.
Our expertise covers the design and execution of patient registries and observational studies that capture real-world treatment patterns, safety outcomes, and disease progression. Clear governance models, protocol adherence, and continuous oversight support data reliability and long-term research value.
We analyze electronic health records, claims databases, and secondary data sources to generate clinically relevant insights. Advanced analytics identify treatment effectiveness, utilization trends, and population-level outcomes while maintaining data traceability, accuracy, and regulatory compliance.
Well-defined protocol development and statistical planning are central to credible RWE studies. We establish clear endpoints, analytical approaches, and data handling plans that support regulatory acceptance, address confounding factors, and strengthen scientific interpretation.
Structured data quality checks, validation processes, and audit-ready workflows ensure accuracy and consistency across real-world datasets. This approach enables the transformation of real-world data into reliable clinical evidence suitable for regulatory review and scientific communication.
Our regulatory-grade RWE services support post-marketing studies, safety monitoring, and product lifecycle evidence needs. Clear methodologies, compliant reporting, and regulator-aligned documentation enable confident submissions to global health authorities and key stakeholders.
FDA Real-World Evidence guidance outlines how real-world data from sources such as electronic health records, claims databases, and patient registries can be used to support regulatory decisions, emphasizing fit-for-purpose study design, data quality, transparency, and appropriate statistical methods to generate reliable evidence for drug, biologic, and medical device approvals, post-marketing studies, and label expansions. ProRelix Research applies FDA Real-World Evidence frameworks to design and execute regulatory-grade observational studies and post-authorization evidence programs, offering expertise in real-world data analytics, protocol development, and compliance-driven reporting to help sponsors generate credible RWE that meets FDA expectations and strengthens regulatory submissions.
ProRelix Research delivers specialized Real-World Evidence (RWE) clinical trial solutions, providing regulatory-aligned study design, high-quality data analytics, and actionable insights. As a leading CRO, we help sponsors generate credible evidence for regulatory submissions, post-marketing studies, and informed healthcare decisions.
We develop tailored RWE study protocols aligned with therapeutic areas and regulatory standards. Our methodology ensures appropriate endpoints, real-world relevance, and data reliability, enabling clients to generate evidence that drives clinical and commercial decision-making.
Optimize patient enrollment through strategic site selection and targeted recruitment methods. We ensure timely enrollment, representative patient populations, and minimal dropouts, helping clients execute RWE studies efficiently while maintaining high-quality data collection across multiple sites.
Collect real-world data from electronic health records, insurance claims, patient registries, and wearable devices. Our integration processes maintain accuracy, consistency, and completeness, turning diverse sources into reliable datasets for clinical, regulatory, and commercial insights.
Ensure full compliance with FDA, EMA, and local regulatory requirements. We monitor patient safety, maintain data integrity, and provide audit-ready documentation, helping clients navigate complex regulations while conducting real-world studies effectively and ethically.
Transform raw real-world data into actionable insights using advanced analytics, predictive modeling, and outcome evaluation. This approach identifies treatment patterns, supports evidence-based decisions, and provides strategic guidance for clinical and commercial objectives.
Deliver regulator-ready reports and publications that clearly summarize study findings. We help clients communicate results effectively to stakeholders, support submissions and publications, and ensure that RWE study outcomes are actionable and easy to interpret.
Real World Evidence (RWE) clinical trials use real-world data from routine healthcare to evaluate treatment safety, effectiveness, and patient outcomes outside traditional controlled studies.
Real World Evidence is derived from routine healthcare settings, while traditional clinical trials follow controlled protocols and predefined study conditions.
RWE helps demonstrate real-life treatment performance across diverse patient populations, supporting evidence-based healthcare and regulatory decision-making.
RWE research includes observational studies, patient registries, retrospective analyses, pragmatic trials, and post-marketing studies.
RWE clinical trials use electronic health records, insurance claims, patient registries, pharmacy data, and digital health data sources.
Yes, agencies such as the FDA and EMA accept RWE for safety evaluation, post-approval commitments, and regulatory submissions.
Data quality is maintained through standardized protocols, validation checks, and regulatory-aligned methodologies, as applied by experienced CROs like ProRelix Research.
Key factors include regulatory expertise, data integrity, study design capabilities, and end-to-end RWE execution experience, which a CRO like ProRelix Research provides with proven expertise in real-world evidence clinical trials.
Bringing a new therapy, device, or health product to market isn’t just about research; it’s about reducing risk, accelerating timelines, and ensuring regulatory confidence. With full-spectrum clinical trial solutions, we help business leaders turn ambitious concepts into market-ready innovations while safeguarding quality and compliance.
Be the first to know the latest trends in clinical research, real-world case studies, and industry secrets.
ProRelix Research is the rapidly growing Contract/ Clinical Research Organization (CRO) with multi-country service capability supporting phase 1, 2, 3, & 4 clinical trials of Pharma, Biotech, Biopharma, Medical Device, Nutraceutical & Herbal companies to conduct in the USA, India, Europe & South East Asia.
